- Home
- LPSN vs CTOR Comparison
LPSN vs CTOR Comparison
Compare LPSN & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPSN
- CTOR
- Stock Information
- Founded
- LPSN 1995
- CTOR 2021
- Country
- LPSN United States
- CTOR United States
- Employees
- LPSN N/A
- CTOR N/A
- Industry
- LPSN EDP Services
- CTOR
- Sector
- LPSN Technology
- CTOR
- Exchange
- LPSN Nasdaq
- CTOR NYSE
- Market Cap
- LPSN 81.6M
- CTOR 89.9M
- IPO Year
- LPSN 2000
- CTOR N/A
- Fundamental
- Price
- LPSN $0.95
- CTOR $0.80
- Analyst Decision
- LPSN Hold
- CTOR Strong Buy
- Analyst Count
- LPSN 5
- CTOR 2
- Target Price
- LPSN $0.98
- CTOR $4.50
- AVG Volume (30 Days)
- LPSN 1.3M
- CTOR 91.8K
- Earning Date
- LPSN 03-05-2025
- CTOR 05-21-2025
- Dividend Yield
- LPSN N/A
- CTOR N/A
- EPS Growth
- LPSN N/A
- CTOR N/A
- EPS
- LPSN N/A
- CTOR N/A
- Revenue
- LPSN $312,474,000.00
- CTOR N/A
- Revenue This Year
- LPSN N/A
- CTOR N/A
- Revenue Next Year
- LPSN $1.72
- CTOR N/A
- P/E Ratio
- LPSN N/A
- CTOR N/A
- Revenue Growth
- LPSN N/A
- CTOR N/A
- 52 Week Low
- LPSN $0.45
- CTOR $0.55
- 52 Week High
- LPSN $2.08
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- LPSN 41.60
- CTOR N/A
- Support Level
- LPSN $0.84
- CTOR N/A
- Resistance Level
- LPSN $1.09
- CTOR N/A
- Average True Range (ATR)
- LPSN 0.07
- CTOR 0.00
- MACD
- LPSN 0.01
- CTOR 0.00
- Stochastic Oscillator
- LPSN 36.52
- CTOR 0.00
About LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation.. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.